29th June 2021

Paralympic Track & Field Athlete David Prince Accepts Sanction for ADRV

USADA announced today that David Prince, of Bradenton, Fla., an athlete in the sport of Paralympic track and field, has accepted a 12-month suspension for an anti-doping rule violation. Prince, 37, tested positive for ostarine (enobosarm), as well as LGD-4033 (ligandrol) and its metabolite di-hydroxy-LGD-4033, as the result of samples collected out of competition on September 27, 2020, October 15, 2020, and November 11, 2020. Ostarine and LGD‐4033 are Non-Specified Substances in the class of Anabolic Agents and are prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic & Paralympic Committee National Anti-Doping Policy, and the International Paralympic Committee Anti-Doping Code, all of which have adopted the World Anti-Doping Code (the Code) and the World Anti-Doping Agency (WADA) Prohibited List.

During USADA’s investigation into the circumstances of his case, USADA received results from a WADA-accredited laboratory that a supplement product Prince was using prior to sample collection, which did not list ostarine and LGD-4033 on the Supplement Facts label, was contaminated with those substances at amounts consistent with the circumstances of ingestion and his positive test. The Code provides the opportunity for a substantial reduction in the otherwise applicable period of ineligibility in this circumstance.

Prince accepted a 12-month period of ineligibility that began on October 16, 2020, the date his provisional suspension was imposed. Prince’s competitive results obtained on and subsequent to September 27, 2020, the date his first positive sample was collected, have been disqualified, including forfeiture of any medals, points and prizes.

• This media release was published by the US Anti-Doping Agency (USADA) on 29 June 2021. Click here for the original.

You may also like...

Pin It on Pinterest

Share This